JP2010523722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523722A5 JP2010523722A5 JP2010503269A JP2010503269A JP2010523722A5 JP 2010523722 A5 JP2010523722 A5 JP 2010523722A5 JP 2010503269 A JP2010503269 A JP 2010503269A JP 2010503269 A JP2010503269 A JP 2010503269A JP 2010523722 A5 JP2010523722 A5 JP 2010523722A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- group
- trail
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 64
- 239000003446 ligand Substances 0.000 claims description 40
- 230000006907 apoptotic process Effects 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000000411 inducer Substances 0.000 claims description 36
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 35
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 125000003107 substituted aryl group Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 150000001717 carbocyclic compounds Chemical class 0.000 claims description 26
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 16
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 16
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 16
- 239000000556 agonist Substances 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims description 14
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
- 230000003463 hyperproliferative effect Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 8
- 101150009046 Tnfrsf1a gene Proteins 0.000 claims description 8
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 125000006242 amine protecting group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 230000006882 induction of apoptosis Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010000050 Abdominal adhesions Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010043189 Telangiectasia Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000013058 Weber syndrome Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
- 201000007293 brain stem infarction Diseases 0.000 claims description 2
- 150000001735 carboxylic acids Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000001969 hypertrophic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 208000009056 telangiectasis Diseases 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 29
- -1 hydrogen compound Chemical class 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 0 CC(*)C*(*)C(*[C@@](C*(*)CC[C@@](CC1)*2[C@]1IC)C2=O)=O Chemical compound CC(*)C*(*)C(*[C@@](C*(*)CC[C@@](CC1)*2[C@]1IC)C2=O)=O 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92334807P | 2007-04-13 | 2007-04-13 | |
| US60/923,348 | 2007-04-13 | ||
| PCT/US2008/060215 WO2008128171A2 (en) | 2007-04-13 | 2008-04-14 | Diazo bicyclic smac mimetics and the uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523722A JP2010523722A (ja) | 2010-07-15 |
| JP2010523722A5 true JP2010523722A5 (OSRAM) | 2012-04-19 |
| JP5416089B2 JP5416089B2 (ja) | 2014-02-12 |
Family
ID=39864640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503269A Active JP5416089B2 (ja) | 2007-04-13 | 2008-04-14 | ジアゾ二環式ｓｍａｃ模倣物およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8278293B2 (OSRAM) |
| EP (1) | EP2139490B1 (OSRAM) |
| JP (1) | JP5416089B2 (OSRAM) |
| KR (1) | KR101081685B1 (OSRAM) |
| CN (1) | CN101686981B (OSRAM) |
| AU (1) | AU2008240119B2 (OSRAM) |
| BR (1) | BRPI0810522B8 (OSRAM) |
| CA (1) | CA2683318C (OSRAM) |
| CY (1) | CY1115735T1 (OSRAM) |
| DK (1) | DK2139490T3 (OSRAM) |
| EA (1) | EA017797B1 (OSRAM) |
| ES (1) | ES2504216T3 (OSRAM) |
| HR (1) | HRP20140885T1 (OSRAM) |
| HU (1) | HUE024142T2 (OSRAM) |
| IL (1) | IL201474A (OSRAM) |
| MX (1) | MX2009011069A (OSRAM) |
| NZ (1) | NZ580468A (OSRAM) |
| PL (1) | PL2139490T3 (OSRAM) |
| PT (1) | PT2139490E (OSRAM) |
| SI (1) | SI2139490T1 (OSRAM) |
| WO (1) | WO2008128171A2 (OSRAM) |
| ZA (1) | ZA200907055B (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| CA2564872C (en) | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| HRP20140885T1 (hr) * | 2007-04-13 | 2014-11-21 | The Regents Of The University Of Michigan | Diazo bicikliäśki smac mimetici i njihove primjene |
| ES2643233T3 (es) | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| CN102666588A (zh) | 2009-11-05 | 2012-09-12 | Uab研究基金会 | 治疗基底细胞样基因型癌症 |
| KR20120140658A (ko) | 2010-02-12 | 2012-12-31 | 파마사이언스 인크. | Ｉａｐ ｂｉｒ 도메인 결합 화합물 |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| JP6247298B2 (ja) * | 2012-08-23 | 2017-12-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｉａｐタンパク質の二価阻害薬およびそれを用いた治療方法 |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2920466C (en) | 2013-09-09 | 2018-10-02 | Halliburton Energy Services, Inc. | Activation of set-delayed cement compositions by retarder exchange |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3151920B1 (en) * | 2014-06-04 | 2025-08-06 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| EP3445759A1 (en) | 2016-04-20 | 2019-02-27 | GlaxoSmithKline Intellectual Property Development Ltd | Conjugates comprising ripk2 inhibitors |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2018102067A2 (en) | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| JP6957620B2 (ja) | 2016-12-01 | 2021-11-02 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体 |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| JP7266526B6 (ja) | 2017-01-26 | 2024-02-15 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体タンパク質分解性の調節因子およびその関連方法 |
| MX2020004074A (es) | 2017-10-19 | 2020-10-16 | Debiopharm Int Sa | Producto de combinacion para el tratamiento de cancer. |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| US11028088B2 (en) | 2018-03-10 | 2021-06-08 | Yale University | Modulators of BTK proteolysis and methods of use |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| JP2022500368A (ja) | 2018-09-07 | 2022-01-04 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法 |
| US20210361774A1 (en) | 2018-10-16 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of lrrk2 |
| EP3886842A1 (en) | 2018-11-26 | 2021-10-06 | Debiopharm International SA | Combination treatment of hiv infections |
| US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
| WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| EP3947368B1 (en) | 2019-04-04 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer |
| CN110028508B (zh) * | 2019-05-16 | 2021-05-28 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| EP4006037A4 (en) | 2019-07-31 | 2023-12-13 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
| MX2022002415A (es) | 2019-08-26 | 2022-03-22 | Arvinas Operations Inc | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
| EP4034102A1 (en) * | 2019-09-25 | 2022-08-03 | Debiopharm International SA | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| JP2023510426A (ja) * | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US12162859B2 (en) | 2020-09-14 | 2024-12-10 | Arvinas Operations, Inc. | Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor |
| CA3179181A1 (en) | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2024022275A1 (zh) | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| AR131299A1 (es) * | 2022-12-09 | 2025-03-05 | Debiopharm Int Sa | Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2026006700A1 (en) * | 2024-06-28 | 2026-01-02 | Regents Of The University Of Michigan | Pyrrolo[1,2-a]-azocine analogues as iap antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| JP2005504043A (ja) * | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| CN1960728A (zh) * | 2004-01-16 | 2007-05-09 | 密歇根大学董事会 | 构象受限的smac模拟物及其应用 |
| US7674787B2 (en) * | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| WO2006010119A2 (en) | 2004-07-09 | 2006-01-26 | Michael Norris | Cargo retaining device for use in vehicle cargo storage areas |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| WO2007130626A2 (en) * | 2006-05-05 | 2007-11-15 | The Regents Of The University Of Michigan | Bivalent smac mimetics and the uses thereof |
| HRP20140885T1 (hr) * | 2007-04-13 | 2014-11-21 | The Regents Of The University Of Michigan | Diazo bicikliäśki smac mimetici i njihove primjene |
| CA2725398A1 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of Michigan | Heteroaryl-substituted bicyclic smac mimetics and the uses thereof |
| US8625740B2 (en) * | 2011-04-14 | 2014-01-07 | Morpho Detection, Inc. | System and method for correcting X-ray diffraction profiles |
-
2008
- 2008-04-14 HR HRP20140885AT patent/HRP20140885T1/hr unknown
- 2008-04-14 EA EA200901400A patent/EA017797B1/ru unknown
- 2008-04-14 ES ES08745750.3T patent/ES2504216T3/es active Active
- 2008-04-14 PT PT87457503T patent/PT2139490E/pt unknown
- 2008-04-14 SI SI200831285T patent/SI2139490T1/sl unknown
- 2008-04-14 CA CA2683318A patent/CA2683318C/en active Active
- 2008-04-14 KR KR1020097023384A patent/KR101081685B1/ko active Active
- 2008-04-14 WO PCT/US2008/060215 patent/WO2008128171A2/en not_active Ceased
- 2008-04-14 PL PL08745750T patent/PL2139490T3/pl unknown
- 2008-04-14 US US12/159,249 patent/US8278293B2/en active Active
- 2008-04-14 HU HUE08745750A patent/HUE024142T2/en unknown
- 2008-04-14 NZ NZ580468A patent/NZ580468A/en not_active IP Right Cessation
- 2008-04-14 DK DK08745750.3T patent/DK2139490T3/da active
- 2008-04-14 CN CN2008800186484A patent/CN101686981B/zh active Active
- 2008-04-14 AU AU2008240119A patent/AU2008240119B2/en not_active Ceased
- 2008-04-14 BR BRPI0810522A patent/BRPI0810522B8/pt active IP Right Grant
- 2008-04-14 EP EP08745750.3A patent/EP2139490B1/en active Active
- 2008-04-14 MX MX2009011069A patent/MX2009011069A/es active IP Right Grant
- 2008-04-14 JP JP2010503269A patent/JP5416089B2/ja active Active
-
2009
- 2009-10-09 ZA ZA2009/07055A patent/ZA200907055B/en unknown
- 2009-10-12 IL IL201474A patent/IL201474A/en active IP Right Grant
-
2012
- 2012-07-25 US US13/557,804 patent/US8664212B2/en active Active
-
2014
- 2014-09-29 CY CY20141100792T patent/CY1115735T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523722A5 (OSRAM) | ||
| CA2683318A1 (en) | Diazo bicyclic smac mimetics and the uses thereof | |
| EP1838320B1 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
| US7026491B2 (en) | Coumarin derivatives useful as TNFα inhibitors | |
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| TW201818937A (zh) | 治療癌症之方法 | |
| JP2020506951A5 (OSRAM) | ||
| JP2011509259A5 (OSRAM) | ||
| KR102598246B1 (ko) | Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도 | |
| CA2854836C (en) | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | |
| JP2011500638A5 (OSRAM) | ||
| JP2014526492A5 (OSRAM) | ||
| CN1312810A (zh) | 作为磷酸二酯酶4抑制剂的取代1,8－二氮杂萘－4(1h)－酮类化合物 | |
| JP2020517598A5 (OSRAM) | ||
| RU2014100744A (ru) | Лечение респираторных нарушений с помощью trpa1 антагонистов | |
| WO2007139150A1 (ja) | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 | |
| RU2671195C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ АРОМАТИЧЕСКОГО ГЕТЕРОЦИКЛИЧЕСКОГО СОЕДИНЕНИЯ, ПРИМЕНЯЕМОГО В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА КИНАЗ JAK3 и/или JAK1, И ПРИМЕНЕНИЕ АРОМАТИЧЕСКОГО ГЕТЕРОЦИКЛИЧЕСКОГО СОЕДИНЕНИЯ | |
| JP7768880B2 (ja) | Ｅｚｈ２を阻害するためのキノリン化合物および組成物 | |
| WO2012047630A2 (en) | N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use | |
| JP2020531454A5 (OSRAM) | ||
| CA2505874A1 (en) | Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease | |
| JP2010540649A5 (OSRAM) | ||
| KR20240012513A (ko) | 세스퀴테르펜 유도체, 그의 약학적 조성물 및 그의 제조 방법과 용도 | |
| JP6982716B2 (ja) | 複素環式化合物及びその使用 | |
| JP2006522039A5 (OSRAM) |